Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Inc. today announced that the National Institute for Health and Care Excellence has recommended LUPKYNIS® as an option for treating adults with active lupus nephritis ... | May 3, 2023

Related Keywords

Rockville ,Maryland ,United States ,United Kingdom ,Great Britain ,Peter Greenleaf ,Healthcare Products Regulatory Agency ,Aurinia Pharmaceuticals Inc ,National Institute For Health ,Nasdaq ,Aurinia Pharmaceuticals ,National Institute ,Care Excellence ,Chief Executive Officer ,European Commission Approved ,Red Cell Aplasia ,Drug Interactions ,Moderate Hepatic Impairment ,Prescribing Information ,Boxed Warning ,Medication Guide ,Renal Response ,Active Lupus With Voclosporin ,Renal Assessments ,Aurinia Renal Response ,Lupus With Voclosporin ,Aurinia Pharmaceuticals Inc Stock Exchange ,News ,Information ,Press Release ,Aurinia ,Pharmaceuticals ,Oday ,Nnounced ,Hat ,The ,Ational ,Institute ,Or ,Health ,End ,Mare ,Excellence ,Gas ,Ecommended ,Us ,N ,Option ,Reating ,Adults ,Ith ,Ctive ,Lupus ,Ephritis Auph Ca05156v1022 ,